Bio-thera Solutions, Ltd. Class ASSE: 688177

"Bio-Thera Solutions, Ltd."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026

Jul 29, 2026 · Issued by Bio-thera Solutions, Ltd. Class A via Shanghai Stock Exchange

Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Bio-thera Solutions, Ltd. Class A

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid TumorsJul 23
"Bio-Thera Solutions, Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual ReportJul 1
Announcement on the Status of the EU GMP Inspection at the Yonghe FacilityJun 15
Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of BAT2206 (Ustekinumab Injection) by Singapore HSAJun 11

All Bio-thera Solutions, Ltd. Class A news releases